Stephan Christgau

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Thrombologic ApS provides medical research and develops therapeutics. The firm develops a new therapy for prevention and treatment of multiple organ failure in Intensive care unit (ICU) patients. The company was founded in December 2009 and is headquartered in Copenhagen, Denmark.

Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark.

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.

Octarine Bio IVS engages in the development of cannabinoid and psychedelic tryptamine derivatives. Its other activities include synthetic biology research. The company was founded by Nicholas Stuart William Milne on September 12, 2018 and is headquartered in Copenhagen, Denmark.